Most biotechs would have shuttered a
clinical program that showed absolutely no efficacy whatsoever in a
late - stage
trial, but Novavax has instead doubled down on RSV by going forth with its
phase 3
trial of the RSV F vaccine for infants via maternal immunization, and begun planning for another
trial in older adults that's reportedly on track to kick off in 2018.
Table 1: Selection, Design & Construction
of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction
of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction
of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction
of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction
of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction
of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored
Clinical Trials of T - Vec Table 8:
Clinical Trials of ColoAd1 Table 9:
Clinical Trials with JX - 594 Table 10:
Clinical Trials with GL - ONC1 Table 11:
Clinical Trials of CAVATAK (CVA21) Table 12:
Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development
Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design
of Oncolytic Viruses in
Late Stage Development Based on Previous
Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active
Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned
Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned
Clinical Studies
of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development
Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed
Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources
of Technology Table 26: Second Generation Oncology Virus Companies and their Sources
of Technology Table 27: Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions